ChemoCentryx Reports Positive PROTECT-1 Study Results For Traficet-EN(TM) At The GASTRO 2009 UEGW/WCOG Conference
Submitted by MedicalReplies on Thursday, 26 November 2009No Comment
ChemoCentryx, Inc., announced that Phase II/III clinical data from the Company’s PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn’s disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn’s disease demonstrated clinical efficacy with a favorable safety and tolerability profile.
Go here to read the rest:
ChemoCentryx Reports Positive PROTECT-1 Study Results For Traficet-EN(TM) At The GASTRO 2009 UEGW/WCOG Conference
Leave your response!